Zimbabwe has rejected a significant American health deal worth 367 million US dollars (£272m) over five years over the United States' request for confidential information.
This move became public following a internal memorandum dated December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the agreement was "lopsided".
A government spokesman later explained that the US was requesting biological samples for research and profit but was unwilling to share the resulting advantages from future vaccines.
"We are forced to start the difficult and regrettable task of winding down our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had provided more than $1.9bn in health funding to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for more dialogue to find a agreement suitable to all parties so the nation's vital HIV programme can be sustained.
Broader Context
Zimbabwe's decision comes after a similar case in Kenya, where a high court suspended a related deal with the US following legal challenges were raised about the security of Kenyans' medical information.
After returning to office last year, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump stated its spending was "inefficient" and his administration was seeking direct bilateral agreements to boost transparency and accountability.
According to statements, Sixteen African countries have so far signed these new agreements, constituting over $18.3bn in committed funds.
Specifics of the Rejected Agreement
The money for Zimbabwe was intended to funded "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this partnership could have provided significant benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently receiving HIV treatment via US-supported programmes," Tremont added.
However, government spokesperson Nick Mangwana said the proposed deal was "unfair".
"The proposal required Zimbabwe to surrender its biological resources and data over an extended period, with no equivalent guarantee of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that provided information," Mangwana explained.
"Put simply, our nation would supply the basic resources for scientific discovery with no certainty that the resulting innovations would be available to our population if a future health crisis emerge."
National Interest and Global Health
He also pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one deals were undermining systems already set up through the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing scheme created to deal with future global health emergencies.
"This framework is designed to guarantee that when a country contributes its information, the benefits – such as medicines and cures – are distributed fairly, not monopolised solely by those with the capability to create them."
These objections regarding the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We are open to ongoing discussions with our American counterparts on how future co-operation could be designed in a way that honours the independence and interests of each country."
Medical Community Response
Medical experts expressed it acknowledged the government's concerns, but urged that negotiations must proceed since a large portion of the country's Aids initiatives were funded by foreign aid.
"In cases where technical issues arise, such as those involving data governance or agreement terms, these can frequently be addressed via detailed discussion and negotiated safeguards," it said.
This impasse emphasises the continuing debate between accepting vital foreign assistance and safeguarding local interests in an increasingly data-driven world.